Investigating a new treatment approach for glaucoma using GLP-1R agonists
Evaluating Mechanisms and Therapeutic Potential of (GLP-1R) Agonists for Glaucoma Treatment
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11087540
This study is looking at how a type of medication called GLP-1R agonists might help protect your eyesight by reducing inflammation in the eye for people with glaucoma, especially those who haven't found relief with standard treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11087540 on ClinicalTrials.gov |
What this research studies
This research explores the potential of glucagon-like peptide-1 receptor (GLP-1R) agonists as a treatment for glaucoma, a condition that leads to vision loss due to the death of retinal ganglion cells. The study aims to understand how these agonists can protect against neurodegeneration by reducing inflammation in the retina. By examining the effects of GLP-1R agonists on microglia and macrophage activity, the researchers hope to identify mechanisms that could lead to new therapeutic strategies for patients who do not respond to traditional intraocular pressure-lowering treatments. If successful, this research could pave the way for innovative treatments that address the underlying causes of glaucoma.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with glaucoma who are experiencing progressive vision loss despite current treatments.
Not a fit: Patients who have not been diagnosed with glaucoma or those whose vision loss is due to other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for glaucoma patients that protects against vision loss without solely relying on lowering eye pressure.
How similar studies have performed: Previous studies have shown promising results with GLP-1R agonists in reducing glaucoma risk, indicating potential for success in this novel approach.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CUI, QI N — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: CUI, QI N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: adult onset diabetes, Adult-Onset Diabetes Mellitus